Hyperosmolar Syndrome

Hyperosmolar syndrome, also known as hyperosmolar hyperglycemic state (HHS), is a life-threatening metabolic emergency characterized by severe hyperglycemia (typically >600 mg/dL), marked hyperosmolality (typically >320 mOsm/kg), and profound dehydration, in the absence of significant ketosis or acidosis. It is most commonly seen in dogs and cats with diabetes mellitus, particularly when insulin therapy is inadequate or omitted, or during periods of stress, infection, or other concurrent illness. The syndrome represents an extreme manifestation of uncontrolled diabetes, where relative insulin deficiency leads to unchecked hepatic glucose production and reduced peripheral glucose utilization, resulting in osmotic diuresis, hypernatremia, and hyperosmolality. Unlike diabetic ketoacidosis (DKA), HHS is characterized by minimal ketone body formation, likely due to residual endogenous insulin secretion sufficient to suppress lipolysis and ketogenesis, but inadequate to control glycemia. The condition is a medical emergency requiring aggressive fluid therapy, insulin administration, and correction of electrolyte imbalances.

The primary etiology of hyperosmolar syndrome is uncontrolled diabetes mellitus, either type 1 (insulin-dependent) or type 2 (non-insulin-dependent), with absolute or relative insulin deficiency. In dogs, diabetes mellitus is almost always insulin-dependent, while cats often have type 2 diabetes with variable insulin resistance. Precipitating factors include: inadequate insulin dosing, missed insulin injections, insulin resistance due to concurrent diseases (e.g., infections, hyperadrenocorticism, hypothyroidism, acromegaly), administration of diabetogenic drugs (e.g., glucocorticoids, progestogens), and severe stress (e.g., surgery, trauma, pancreatitis). In some cases, HHS may be the initial presentation of diabetes mellitus. The syndrome can also occur in non-diabetic patients with severe hyperglycemia due to total parenteral nutrition, certain medications, or endocrine disorders such as pheochromocytoma. The underlying molecular trigger is severe insulin deficiency, leading to increased hepatic gluconeogenesis and glycogenolysis, decreased peripheral glucose uptake, and osmotic diuresis.

Hyperosmolar syndrome is less common than diabetic ketoacidosis in veterinary medicine, but it is a significant cause of morbidity and mortality in diabetic dogs and cats. It can occur in any breed, age, or sex, but is more frequently seen in middle-aged to older animals, with a median age of 8-10 years in dogs and 10-12 years in cats. There is no strong breed predisposition, but conditions that predispose to diabetes mellitus, such as obesity in cats and chronic pancreatitis in dogs, increase the risk. The incidence is higher in animals with poorly controlled diabetes, and it is often precipitated by concurrent illness, such as urinary tract infections, pneumonia, or pancreatitis. Geographic and seasonal variations are not well-documented, but stress-related events may increase risk. In cats, transient diabetes and remission can complicate the epidemiology, as HHS may occur during relapse.

The pathophysiology of hyperosmolar syndrome begins with severe insulin deficiency, which reduces glucose uptake by insulin-sensitive tissues (muscle, adipose, liver) and increases hepatic glucose production via gluconeogenesis and glycogenolysis. This leads to marked hyperglycemia, typically exceeding the renal threshold for glucose (approximately 180-220 mg/dL in dogs and cats), causing osmotic diuresis. The osmotic diuresis results in loss of water and electrolytes (sodium, potassium, chloride) in the urine, leading to dehydration, hypernatremia, and hyperosmolality. As plasma osmolality rises, water shifts from the intracellular to the extracellular space, causing cellular dehydration, particularly in the brain, which can lead to neurological signs such as depression, coma, and seizures. Unlike DKA, ketone body production is minimal because residual insulin secretion, though inadequate for glycemic control, is sufficient to suppress lipolysis and hepatic ketogenesis. However, some patients may have a mixed picture with mild ketosis. The hyperosmolality also impairs pancreatic beta-cell function and insulin secretion, creating a vicious cycle. Additionally, hyperglycemia causes a hypercoagulable state, increasing the risk of thromboembolism. The severe dehydration and hyperosmolality can lead to prerenal azotemia, acute kidney injury, and cardiovascular collapse if untreated.

Predisposing factors for hyperosmolar syndrome include: (1) Inadequate insulin therapy: missed doses, incorrect dosing, or insulin resistance due to anti-insulin antibodies or poor absorption. (2) Concurrent diseases: infections (urinary tract, respiratory, dental), pancreatitis, hyperadrenocorticism, hypothyroidism, acromegaly, chronic kidney disease, and cardiac disease. (3) Medications: glucocorticoids, progestogens, thiazide diuretics, and sympathomimetics. (4) Stress: surgery, trauma, hospitalization, or environmental changes. (5) Obesity: particularly in cats, as it contributes to insulin resistance. (6) Age: older animals are more prone to concurrent diseases and insulin resistance. (7) Breed: certain breeds, such as Samoyeds and Keeshonden, have a higher incidence of immune-mediated diabetes, but HHS itself has no specific breed predilection. (8) Poor owner compliance: inadequate monitoring of blood glucose and insulin administration.

Clinical signs of hyperosmolar syndrome are often insidious and may be present for several days before presentation. They include: (1) Polyuria and polydipsia, which may be severe but can be masked by dehydration. (2) Lethargy, weakness, and depression. (3) Anorexia and vomiting, which may lead to further dehydration. (4) Weight loss, despite polyphagia in some cases. (5) Dehydration, as evidenced by decreased skin turgor, dry mucous membranes, and prolonged capillary refill time. (6) Neurological signs: in severe hyperosmolality (>350 mOsm/kg), animals may show ataxia, stupor, coma, or seizures. (7) Tachycardia and weak pulses due to hypovolemia. (8) In cats, a plantigrade stance may be observed due to diabetic neuropathy. (9) Physical examination may reveal hepatomegaly, cataracts (in dogs), and signs of concurrent infections (e.g., fever, pyoderma, urinary tract infection). The clinical signs can be categorized by stage: peracute (rapid onset of severe signs), acute (classic signs), subacute (progressive signs over days), chronic (long-standing uncontrolled diabetes), and terminal (coma, shock).

Differential diagnoses for hyperosmolar syndrome include: (1) Diabetic ketoacidosis (DKA): distinguished by the presence of ketonemia/ketonuria and metabolic acidosis; HHS has minimal ketosis and normal or slightly low pH. (2) Uremic encephalopathy: due to chronic kidney disease, characterized by azotemia, isosthenuria, and hyperphosphatemia; blood glucose is usually normal. (3) Hepatic encephalopathy: due to liver failure, with elevated liver enzymes, hyperammonemia, and abnormal bile acids; blood glucose may be low or normal. (4) Intracranial disease (e.g., brain tumor, trauma, infection): neurological signs may mimic HHS, but blood glucose and osmolality are normal. (5) Hypernatremia from other causes (e.g., diabetes insipidus, salt poisoning): blood glucose is normal, and osmolality is elevated due to sodium. (6) Sepsis or systemic inflammatory response syndrome: may cause hyperglycemia but not to the extreme levels of HHS; blood cultures and inflammatory markers help differentiate. (7) Hyperthyroidism in cats: can cause hyperglycemia due to stress, but not severe hyperosmolality; thyroid hormone levels are elevated. (8) Acromegaly in cats: causes insulin resistance and diabetes, but HHS is a complication; growth hormone and IGF-1 levels are elevated. (9) Pheochromocytoma: causes hyperglycemia and hypertension; catecholamine levels are elevated. (10) Exogenous glucocorticoid administration: can cause hyperglycemia, but history and cortisol levels help differentiate.

The diagnostic algorithm for hyperosmolar syndrome begins with a thorough history and physical examination, focusing on hydration status, neurological status, and signs of concurrent disease. Immediate point-of-care testing should include blood glucose (typically >600 mg/dL), blood urea nitrogen (BUN), packed cell volume (PCV), total solids, and urine dipstick for glucose and ketones. If hyperglycemia is confirmed, a serum biochemistry panel, complete blood count, and venous blood gas analysis should be performed. Key diagnostic criteria include: blood glucose >600 mg/dL, serum osmolality >320 mOsm/kg (calculated as 2(Na+ + K+) + glucose/18 + BUN/2.8), and absence of significant ketonemia (beta-hydroxybutyrate <3 mmol/L) and acidosis (pH >7.3, bicarbonate >18 mEq/L). Urinalysis should be performed to assess for ketonuria, urinary tract infection, and renal function. Additional tests may include serum fructosamine to assess long-term glycemic control, and specific tests for concurrent diseases (e.g., cortisol/ACTH stimulation for hyperadrenocorticism, thyroid hormone levels, pancreatic lipase immunoreactivity for pancreatitis). Imaging (abdominal ultrasound, thoracic radiographs) may be indicated to identify underlying causes such as pancreatitis, adrenal tumors, or infections. The diagnostic algorithm should proceed from initial stabilization to confirmatory testing, with continuous monitoring of glucose, electrolytes, and osmolality during treatment.

Laboratory findings in hyperosmolar syndrome include: (1) Hematology: hemoconcentration (increased PCV and total solids), stress leukogram (neutrophilia, lymphopenia, eosinopenia), and possibly thrombocytopenia if sepsis is present. (2) Serum biochemistry: marked hyperglycemia (>600 mg/dL), hypernatremia (often >150 mEq/L), hyperosmolality (>320 mOsm/kg), prerenal azotemia (elevated BUN and creatinine), elevated liver enzymes (ALT, ALP) due to hepatic lipidosis or stress, and hypercholesterolemia. Electrolyte disturbances: total body potassium depletion despite normal or low serum potassium due to osmotic diuresis; hyponatremia may occur if water intake is excessive, but hypernatremia is more common. (3) Urinalysis: glucosuria (4+), ketonuria may be absent or trace, urine specific gravity may be low (<1.020) due to osmotic diuresis, and evidence of urinary tract infection (pyuria, bacteriuria). (4) Blood gas analysis: pH is typically normal or slightly acidotic (7.3-7.4), bicarbonate is normal or slightly low, and there is no significant anion gap. (5) Specific biomarkers: serum fructosamine is elevated (>400 μmol/L in dogs, >350 μmol/L in cats), reflecting poor glycemic control over the past 2-3 weeks. (6) Endocrine assays: if concurrent hyperadrenocorticism is suspected, ACTH stimulation test or low-dose dexamethasone suppression test may be performed. (7) Additional tests: serum lipase and pancreatic lipase immunoreactivity (PLI) to rule out pancreatitis, and blood cultures if sepsis is suspected.

Imaging findings in hyperosmolar syndrome are primarily used to identify underlying or concurrent diseases. (1) Thoracic radiographs: may show evidence of pneumonia, cardiomegaly, or pulmonary edema if heart failure is present. (2) Abdominal radiographs: may reveal hepatomegaly, which is common in diabetic animals due to hepatic lipidosis or glycogen accumulation. (3) Abdominal ultrasound: is particularly useful to evaluate the pancreas (for pancreatitis), adrenal glands (for hyperadrenocorticism), liver (for lipidosis or neoplasia), and kidneys (for chronic kidney disease). In pancreatitis, the pancreas may be hypoechoic with surrounding hyperechoic mesentery. In hyperadrenocorticism, bilateral adrenal enlargement may be seen. (4) Echocardiography: may be indicated if cardiac disease is suspected, as diabetic animals are prone to cardiomyopathy. (5) Computed tomography (CT) or magnetic resonance imaging (MRI): may be used to evaluate the pituitary gland if acromegaly is suspected in cats, or to assess for intracranial lesions if neurological signs are present. (6) Endoscopy: not typically indicated, but may be used to evaluate for gastrointestinal disease if vomiting is severe.

Cytology and histopathology are not routinely performed for the diagnosis of hyperosmolar syndrome itself, but may be used to evaluate concurrent diseases. (1) Fine needle aspirate (FNA) of the liver: may reveal hepatic lipidosis (vacuolated hepatocytes) or glycogen accumulation. (2) FNA of the pancreas: may show inflammatory cells if pancreatitis is present, but is rarely performed due to risk. (3) Histopathology of the pancreas: in diabetic animals, may show islet cell degeneration, amyloidosis (in cats), or lymphocytic infiltration (immune-mediated). (4) Histopathology of the liver: may show lipidosis, glycogen deposition, or cirrhosis. (5) Cytology of urine: may reveal bacteria and inflammatory cells if urinary tract infection is present. (6) Histopathology of the adrenal glands: if hyperadrenocorticism is suspected, may show hyperplasia or neoplasia. These findings are not specific to HHS but help identify underlying causes.

Treatment of hyperosmolar syndrome is a medical emergency and should be initiated immediately. The goals are to correct hypovolemia, hyperosmolality, electrolyte imbalances, and hyperglycemia gradually, while treating any underlying precipitating causes. (1) Fluid therapy: Initial fluid resuscitation with 0.9% sodium chloride (NaCl) at a rate of 10-20 mL/kg IV over 15-30 minutes in shock, then maintenance at 60-100 mL/kg/day. The rate should be adjusted based on hydration status, urine output, and cardiovascular status. Once blood glucose falls below 250 mg/dL, switch to 0.45% NaCl with 2.5% dextrose to prevent hypoglycemia and rapid osmolality shifts. (2) Insulin therapy: Regular crystalline insulin (e.g., Humulin R) is administered IV as a continuous rate infusion (CRI) at an initial dose of 0.05-0.1 U/kg/hour, or as intermittent intramuscular (IM) injections (0.2 U/kg initially, then 0.1 U/kg/hour). The insulin dose should be titrated based on blood glucose measurements every 1-2 hours, aiming for a gradual decrease in glucose (50-75 mg/dL/hour). Once glucose is <250 mg/dL, add dextrose to the fluids and reduce insulin infusion rate. (3) Electrolyte replacement: Potassium chloride (KCl) should be added to fluids at 20-40 mEq/L, based on serum potassium levels, to prevent hypokalemia. If potassium is <3.5 mEq/L, aggressive supplementation is needed. (4) Correction of acidosis: In HHS, acidosis is usually mild, but if pH <7.1, sodium bicarbonate may be administered (0.5-1 mEq/kg IV over 30 minutes). (5) Treatment of underlying causes: Antibiotics for infections, management of pancreatitis, and adjustment of insulin therapy for concurrent endocrine diseases. (6) Monitoring: Frequent monitoring of blood glucose, electrolytes, osmolality, and urine output is essential. (7) Nutritional support: Once the patient is stable, a high-fiber, complex-carbohydrate diet is recommended for diabetic management. (8) Supportive care: Anti-nausea medications (e.g., maropitant 1 mg/kg IV q24h), gastroprotectants (e.g., omeprazole 1 mg/kg IV q24h), and nutritional support via feeding tube if anorexic.

The prognosis for hyperosmolar syndrome is guarded to poor, with reported mortality rates of 20-40% in dogs and cats. Factors associated with a worse prognosis include: severe hyperosmolality (>350 mOsm/kg), presence of neurological signs (coma, seizures), concurrent diseases (pancreatitis, sepsis, renal failure), and delayed treatment. Early and aggressive fluid therapy and insulin administration improve outcomes. In cats, if the underlying cause is transient diabetes, remission may be possible, but if HHS occurs, the prognosis for long-term survival is worse. In dogs, diabetes is permanent, and lifelong insulin therapy is required. With appropriate management, many animals can survive the acute episode and have a good quality of life, but they require close monitoring and owner compliance.

Follow-up care for hyperosmolar syndrome is critical to prevent recurrence and manage diabetes. After discharge, patients should be re-evaluated within 1-2 weeks for a full physical examination, blood glucose curve, serum fructosamine, and assessment of hydration and electrolyte status. Insulin therapy should be adjusted based on serial blood glucose measurements (e.g., every 2-4 hours for a 12-24 hour curve). Long-term monitoring includes: (1) Blood glucose curves at home or in the clinic every 2-4 weeks initially, then every 3-6 months. (2) Serum fructosamine every 2-3 months to assess glycemic control. (3) Urinalysis and urine culture every 3-6 months to screen for urinary tract infections. (4) Blood pressure measurement to monitor for hypertension. (5) Ophthalmic examinations every 6-12 months to detect cataracts (in dogs) or diabetic retinopathy. (6) Monitoring for concurrent diseases (e.g., pancreatitis, hyperadrenocorticism) with appropriate tests. (7) Owner education on insulin administration, diet, and recognition of signs of hypoglycemia and hyperglycemia. (8) Emergency plan for sick days, including instructions for insulin dose adjustments and when to seek veterinary care.

Pearls: (1) Always calculate serum osmolality in any diabetic patient with severe hyperglycemia; it guides fluid therapy. (2) Use 0.9% NaCl for initial fluid resuscitation to avoid rapid drops in osmolality, which can cause cerebral edema. (3) Add potassium to fluids early, as insulin therapy will drive potassium into cells, causing hypokalemia. (4) Monitor blood glucose every 1-2 hours during initial treatment to titrate insulin infusion. (5) Look for and treat underlying infections, as they are common precipitating factors. (6) In cats, consider acromegaly if insulin requirements are high. Pitfalls: (1) Administering insulin before adequate fluid resuscitation can cause severe hypokalemia and arrhythmias. (2) Rapid correction of hyperglycemia with high insulin doses can lead to hypoglycemia and cerebral edema. (3) Using lactated Ringer's solution (which contains lactate) may worsen hyperglycemia. (4) Failing to monitor electrolytes can lead to life-threatening imbalances. (5) Discontinuing insulin once glucose normalizes without transitioning to maintenance insulin can cause recurrence. (6) Overlooking concurrent diseases such as pancreatitis or hyperadrenocorticism can lead to treatment failure.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for hyperosmolar syndrome: (1) Insulin regular (Humulin R): IV CRI at 0.05-0.1 U/kg/hour, or IM initial dose 0.2 U/kg, then 0.1 U/kg/hour. Adjust based on glucose. (2) Potassium chloride (KCl): Add to IV fluids at 20-40 mEq/L, depending on serum potassium. If potassium <3.5 mEq/L, give 0.4 mEq/kg/hour IV for 4-6 hours, then reassess. (3) Sodium bicarbonate: Only if pH <7.1, give 0.5-1 mEq/kg IV over 30 minutes. (4) Antibiotics: If infection is suspected, e.g., amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or enrofloxacin (5-10 mg/kg PO/IV q24h). (5) Antiemetics: Maropitant (1 mg/kg IV/SC q24h) or ondansetron (0.5-1 mg/kg IV q12h). (6) Gastroprotectants: Omeprazole (1 mg/kg IV/PO q24h) or famotidine (0.5-1 mg/kg IV/PO q12h). (7) Dextrose: 2.5% dextrose in fluids when glucose <250 mg/dL. (8) For concurrent hyperadrenocorticism: Trilostane (2-5 mg/kg PO q24h) or mitotane (50 mg/kg/day for 7-10 days, then 50 mg/kg/week). (9) For pancreatitis: Analgesics such as buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) and supportive care. (10) For acromegaly in cats: Radiation therapy or medical management with somatostatin analogs (e.g., pasireotide) is experimental. All dosages should be adjusted based on renal/hepatic function and patient response.

Evidence-based literature on hyperosmolar syndrome in veterinary medicine is limited, but key studies include: (1) A retrospective study by Hume et al. (2006) in dogs with HHS reported a mortality rate of 30%, with neurological signs and hyperosmolality >350 mOsm/kg associated with poor prognosis. (2) A study by Durocher et al. (2008) in cats with HHS found that concurrent diseases, particularly pancreatitis, were common and increased mortality. (3) Consensus guidelines from the American Animal Hospital Association (AAHA) and the International Society for Canine and Feline Endocrinology (ISCFE) recommend a gradual reduction of blood glucose (50-75 mg/dL/hour) to prevent cerebral edema. (4) A study by Zeugswetter et al. (2010) compared fluid therapy protocols and found that 0.9% NaCl was superior to lactated Ringer's for initial resuscitation. (5) Research on insulin therapy suggests that low-dose IV CRI is safer and more effective than high-dose intermittent injections. (6) A meta-analysis by O'Brien et al. (2015) emphasized the importance of potassium supplementation to prevent hypokalemia. (7) The ACVIM consensus statement on diabetes mellitus (2018) provides evidence-based recommendations for monitoring and management, including the use of fructosamine and blood glucose curves. (8) Studies on feline diabetes have shown that tight glycemic control can lead to remission, but HHS is a negative predictor. Overall, the evidence supports aggressive fluid therapy, careful insulin administration, and treatment of underlying causes to improve outcomes.